






RECEIVED

APR 18 2001

TECH CENTER 1600810001 of 1

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b>	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AA	Rico, J.G. et al., "A highly stereoselective michael addition to an $\alpha$ , $\beta$ -unsaturated ester as the crucial step in the synthesis of a novel beta-amino acid-containing fibrinogen receptor antagonist", <del>J. Org. Chem., 1993, Vol. 58, pp. 7948-7951</del>	
	AB	Zablocki, J.A. et al., "Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequences of fibrinogen", <i>J. Med. Chem.</i> , 1995, Vol. 38, pp. 2378-2394	
EXAMINER 		DATE CONSIDERED <b>12/3 /01</b>	

## Form PTO-1449 Modified

Docket No.  
CELL-0072  
(PA 439.3)Serial No.  
09/326,020Applicant  
John Robert Porter, et al.,Filing Date  
June 4, 1999Group  
1625

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

## U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
1/18/02 <i>BMR</i>	AA	5,399,585	03/21/95	Alig, et al.	514	438

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AB	WO 97/24124	07/10/97	PCT		
<i>BMR</i>	AC	WO 00/31067	06/02/00	PCT	✓	

EXAMINER

*Binto /bl*

DATE CONSIDERED

*12/3/01*



Form <b>PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b> <b>(PA 439.3)</b>	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter, et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AA</b>	Alhaique, F., et al., "Cyclisation of dinitriles by sodium alkoxides a new synthesis of naphthyridines," <i>Tetrahedron Letters</i> , <b>1975</b> , 3, 173-174	
	<b>AB</b>	Ames, D.E., et al., "Condensation of $\beta$ -dicarbonyl compounds with halogenopyridinecarb-oxylic acids. A convenient synthesis of some naphthyridine derivatives," <i>J.C.S. Perkin I</i> , <b>1972</b> , 705-710	
	<b>AC</b>	Bodor, N., "Novel approaches in prodrug design," <i>Alfred Benzon Symposium</i> , <b>1982</b> , 17, 156-177	
	<b>AD</b>	Brooks, Peter C., et al., "Antiintegrin $\alpha\beta 3$ blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> , <b>1995</b> , 96, 1815-1822	
*	<b>AE</b>	Bundgaard, H., <i>Design of Prodrugs</i> , <b>1985</b> , Elsevier, Amsterdam	
*	<b>AF</b>	Katritzky, A.R., et al. (Eds.), <i>Comprehensive Organic Functional Group Transformations</i> , Pergamon, <b>1995</b>	
	<b>AG</b>	Davies, S.G., et al., "Asymmetric synthesis of R- $\beta$ -amino butanoic acid and S- $\beta$ -tyrosine: homochiral-lithium amide equivalents for Michael additions to $\alpha,\beta$ -unsaturated esters," <i>Tetra. Asymmetry</i> , <b>1991</b> , 2(3), 183-186	
	<b>AH</b>	Erle, D.J., et al., "Expression and function of the MacCAM-1 receptor, integrin $\alpha 4 \beta 7$ , on human leukocytes," <i>J. Immunol.</i> , <b>1994</b> , 153, 517-528	
*	<b>AI</b>	Encyclopedia of Reagents for Organic Synthesis, <i>John Wiley and Sons (eds.)</i> , <b>1995</b>	
	<b>AJ</b>	Giacomello, et al., "Synthesis of 2,6-naphthyridine," <i>Tetra. Letters</i> , <b>1965</b> , 16, 1117-1121	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	
Binta Robinson		12/3/0	


\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b> (PA 439.3)	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter, et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	AK	Green, T.W., et al., "Protective Groups in Organic Synthesis," <i>John Wiley and Sons</i> (eds.), 1991	
	AL	Hammes, H., et al., "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Medicine</i> , 1996, 2, 529-533	
	AM	Hodivala-Dilke, K.M., "β3-integrin-deficient mice are a model for glanzmann thrombasthenia showing placental defects and reduced survival," <i>J. Clin. Invest.</i> , 1999, 103(2), 229-238	
	AN	Kalvin, D.M., et al., Synthesis of (4R)-D,L-[4- <sup>2</sup> H]- and (4S)-D,L-[4- <sup>2</sup> H] homoserine lactones," <i>J. Org. Chem.</i> , 1985, 50, 2259-2263	
	AO	Koivunen, E., et al., "Selection of peptides binding to the α <sub>5</sub> β <sub>1</sub> integrin from phage display library," <i>J. Biological Chemistry</i> , 1993, 268(27), 20205-20210	
	AP	Mitjans, F., et al., "An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," <i>J. Cell Science</i> , 1995, 108, 2825-2838	
	AQ	Molina, P., et al., "Iminophosphorane-mediated annelation of a pyridine ring into a preformed pyridine one: synthesis of naphthyridine, pyrido [1,2-c] pyrimidine and pyrido [1,2-c] quinazoline derivatives," <i>Tetrahedron</i> , 1992, 48(22), 4601-4616	
	AR	Newham, P., et al., "Integrin adhesion receptors: structure, function and implications for biomedicine," <i>Molecular Medicine Today</i> , 1996, 304-313	
	AS	Numata, A., et al., "General synthetic method for naphthyridines and their N-oxides containing isoquinolinic nitrogen," <i>Synthesis</i> , 1999, 2, 306-311	
	AT	Sakamoto, T., et al., "Condensed heteroaromatic ring systems. III. synthesis of naphthyridine derivatives by cyclization of ethynylpyridinecarboxamides," <i>Chem. Pharm. Bull.</i> 1985, 33(2), 626-633	
EXAMINER		DATE CONSIDERED	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>CELL-0072</b> <b>(PA 439.3)</b>	Serial No. <b>09/326,020</b>
		Applicant <b>John Robert Porter, et al.</b>	
		Filing Date <b>June 4, 1999</b>	Group <b>1625</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<del>AU</del>	<del>Singh, G., et al., "Prodrug approach in new drug design and development," <i>J. Sci. Ind. Res.</i>, 1996, 55, 497-510</del>		
<del>AV</del>	<del>Srivatsa, S.S., et al., "Selective <math>\alpha\text{v}\beta 3</math> integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin <math>\alpha\text{v}\beta 3</math> and osteopontin expression during neointima formation," <i>Cardiovascular Research</i>, 1997, 36, 408-428</del>		
<del>AW</del>	<del>Stupack, D.G., et al., "induction of <math>\alpha\text{v}\beta 3</math> integrin-mediated attachment to extracellular matrix in <math>\beta 1</math> integrin (CD29)-negative B cell lines," <i>Experi. Cell Research</i>, 1992, 203, 443-448</del>		
<del>AX</del>	<del>Tan R., et al., "Synthesis of 2, 6-naphthyridine and some of its derivatives," <i>Tetrahedron Letters</i>, 1965, 31, 2737-2744</del>		
<b>EXAMINER</b> 		<b>DATE CONSIDERED</b> 12/3/01	

Form ~~PTO~~ 1449 ModifiedDocket No.  
CELL-0072  
(PA 439.3)Serial No.  
09/326,020List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
John Robert Porter, et al.U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
June 4, 1999Group  
1625

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	AY	WO 97/23480	07/03/97	PCT		
	AZ	WO 97/36858	10/09/97	PCT		
	BA	WO 97/36861	10/09/97	PCT		
	BB	WO 97/36862	10/09/97	PCT		
	BC	WO 97/44333	11/27/97	PCT	X (Abstract)	
	BD	WO 97/47618	12/18/97	PCT		
	BE	WO 98/04247	02/05/98	PCT		
	BF	WO 98/18460	05/07/98	PCT		
	BG	WO 98/25892	06/18/98	PCT		
	BH	WO 98/31359	07/23/98	PCT		
	BI	WO 99/26921	06/03/99	PCT		
	BJ	WO 99/26922	06/03/99	PCT		
	BK	WO 99/26945	06/03/99	PCT		
	BL	WO 99/31061	06/24/99	PCT		
	BM	WO 99/31099	06/24/99	PCT		
	BN	WO 99/32457	07/01/99	PCT		
	BO	WO 99/36393	07/22/99	PCT		
	BP	WO 99/44994	09/10/99	PCT		
	BQ	WO 99/52879	10/21/99	PCT		
	BR	WO 99/52896	10/21/99	PCT		
	BS	WO 99/52898	10/21/99	PCT		

EXAMINER

DATE CONSIDERED

12/3/01

